HIGHLIGHTS
- who: Qiu Li from the National Research University Higher School of Economics, Russia have published the paper: Lenvatinib Plus Pembrolizumab vs. Chemotherapy in Pretreated Patients With Advanced Endometrial Cancer: A Cost-Effectiveness Analysis, in the Journal: (JOURNAL)
SUMMARY
In preclinical models and has shown more potent antitumor activity than either agent alone. The phase 3 study 309-KEYNOTE-775 (NCT03517449) showed lenvatinib plus pembrolizumab (LP) prolonged progression-free survival (PFS) and overall survival (OS), compared with chemotherapy among platinum-based chemotherapy pretreated patients with advanced endometrial cancer. This costeffectiveness analysis aimed to compare . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.